{"id":"W2081446512","doi":"10.1038/bcj.2014.71","title":"Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Takeda Pharmaceuticals International; Takeda Oncology; Weill Cornell Medical College","keywords":"Medicine; Ixazomib; Follicular lymphoma; Nausea; Internal medicine; Neutropenia; Tolerability; Adverse effect; Pharmacodynamics; Gastroenterology; Lymphoma; Proteasome inhibitor; Pharmacokinetics; Pharmacology; Multiple myeloma; Toxicity; Carfilzomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007718517,0.001140634,0.00195652,0.0003492776,0.0002170474,0.0005559267,0.0005810288,0.0005963694,0.001230289],"category_scores_gemma":[0.0007136355,0.0003928931,0.0006040245,0.0003188584,0.0005300167,0.0004501647,0.0002167746,0.002138801,0.0003486792],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007915405,"about_ca_system_score_gemma":0.0005951271,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004481532,"about_ca_topic_score_gemma":0.001167433,"domain_scores_codex":[0.9997013,0.0001475675,0.00001178169,0.00004544588,0.00003018855,0.00006370177],"domain_scores_gemma":[0.9996405,0.00006622725,0.0001045044,0.00002707308,0.00001679109,0.0001449067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4270591,0.07421465,0.02193944,0.001068229,0.00117817,0.001103115,0.0008919997,0.00737291,0.167832,0.0003751579,0.004843245,0.2921222],"study_design_scores_gemma":[0.2214631,0.7254421,0.03490394,0.0000471543,0.0003181927,0.0009291823,0.00007465039,0.003190067,0.009992347,0.0002190091,0.003380943,0.00003940449],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996632,0.001460963,0.0003422268,0.0001514667,0.00003237436,0.0004993797,0.0001747683,0.00005855031,0.0006482047],"genre_scores_gemma":[0.9951143,0.001129812,0.001133269,0.000314804,0.00007452691,0.0005957566,0.0006531544,0.0000150602,0.0009692492],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00195652,"threshold_uncertainty_score":0.005743027,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01404684565484182,"score_gpt":0.2736524728493425,"score_spread":0.2596056271945006,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}